Xiaowen Tang
YOU?
Author Swipe
View article: Carbon Finance and Dynamic Capital Structure Adjustment
Carbon Finance and Dynamic Capital Structure Adjustment Open
Dynamic adjustment of capital structure is crucial for corporate financial stability and long-term resource allocation, and it is also an important foundation for sustainable economic development. In the context of global climate change, c…
View article: IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial Open
View article: Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline
Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline Open
View article: Tandem <scp>CD19</scp>/<scp>CD22 CAR</scp> T‐Cell Therapy as First‐Line Treatment for Adult Patients With High‐Risk Philadelphia Chromosome Negative B‐Cell Acute Lymphoblastic Leukemia
Tandem <span>CD19</span>/<span>CD22 CAR</span> T‐Cell Therapy as First‐Line Treatment for Adult Patients With High‐Risk Philadelphia Chromosome Negative B‐Cell Acute Lymphoblastic Leukemia Open
View article: Supplementary Table S2 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S2 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Complete remissions in subpopulations by assigned treatment group
View article: Supplementary Table S1 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S1 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Representativeness of Study Participants
View article: Supplementary Table S5 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S5 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Hematologic and non-hematologic toxicity related to induction chemotherapy
View article: Supplementary Table S3 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S3 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Measurable residual disease (MRD) response analysis
View article: Supplementary Table S4 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S4 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Survival analysis
View article: Data from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Data from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Purpose:To assess the efficacy and safety of an induction regimen composed of idarubicin, cytarabine, and cladribine (IAC) in patients with de novo acute myeloid leukemia (AML).Patients and Methods:Adult patients with newly diagnose…
View article: CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial Open
Approximately 78.3% of patients with t(8;21) acute myeloid leukemia (AML) express CD19, making it a potential target for chimeric antigen receptor (CAR)-T cell therapy focused on CD19. This prospective phase II trial (NCT03896854) evaluate…
View article: Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients Open
Relapse and refractory T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma (R/R T‐ALL/LBL) patients have poor outcomes. Chimeric antigen receptor (CAR)‐T‐cell therapy for T‐ALL/LBL has shown encouraging results in the early stag…
View article: Signet ring cell carcinoma of the appendix and terminal ileum: A case report
Signet ring cell carcinoma of the appendix and terminal ileum: A case report Open
BACKGROUND Appendiceal signet-ring cell carcinoma (SRCC) with terminal ileum metastasis is extremely rare. There have been no reported cases in domestic and foreign literature. CASE SUMMARY In this case report, we present an 88-year-old ma…
View article: Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed <i>CBF</i>β<i>::MYH11+</i> acute myeloid leukemia
Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed <i>CBF</i>β<i>::MYH11+</i> acute myeloid leukemia Open
Not available.
View article: Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab Open
View article: IL-6 Knockdown Anti-CD19 CAR-T Cells (ssCART-19) for Patients with Relapsed or Refractory Acute Lymphoblastic Leukaemia: Phase 1 Trial
IL-6 Knockdown Anti-CD19 CAR-T Cells (ssCART-19) for Patients with Relapsed or Refractory Acute Lymphoblastic Leukaemia: Phase 1 Trial Open
View article: Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Strategy for Treating Refractory Immune-Mediated Platelet Transfusion Refractoriness
Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Strategy for Treating Refractory Immune-Mediated Platelet Transfusion Refractoriness Open
View article: Diesel Exhaust Induces Hepatic Steatosis by Activating the Aryl Hydrocarbon Receptor/Cd36 Pathway
Diesel Exhaust Induces Hepatic Steatosis by Activating the Aryl Hydrocarbon Receptor/Cd36 Pathway Open
View article: Correction: Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
Correction: Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group Open
View article: [Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy].
[Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy]. Open
Objective: This study aimed to analyze cytomegalovirus (CMV) reactivation and its influencing factors in patients with B-lymphocyte malignancy who received chimeric antigen receptor T (CAR-T) cell therapy. Methods: This study…
View article: Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation Open
View article: Safe and potent anti‐CD19 CAR T‐cells with shRNA‐IL‐6 gene silencing element in patients with refractory or relapsed B‐cell acute lymphoblastic leukemia
Safe and potent anti‐CD19 CAR T‐cells with shRNA‐IL‐6 gene silencing element in patients with refractory or relapsed B‐cell acute lymphoblastic leukemia Open
Severe cytokine release syndrome (sCRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) have limited the widespread use of chimeric antigen receptor T (CAR T)‐cell therapy. We designed a novel anti‐CD19 CAR (ssCART‐19) w…
View article: Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia
Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia Open
Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid le…
View article: Familial Acute Promyelocytic Leukemia: A Case Report and Review of the Literature
Familial Acute Promyelocytic Leukemia: A Case Report and Review of the Literature Open
Acute promyelocytic leukemia (APL) is characterized by a reciprocal translocation t (15;17) (q24;q21), which leads to the fusion of PML and RARα genes known as PML-RARα fusion. A few cases of potentially hereditary leukemia-related …
View article: Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation
Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation Open
This study aimed to evaluate the efficacy and safety of chidamide (Chi) combined with a modified Busulfan-Cyclophosphamide (mBuCy) conditioning regimen for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) patients undergoing alloge…
View article: Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia Open
Acute myeloid leukemia (AML) is the most frequent leukemia in adults with a high mortality rate. Current diagnostic criteria and selections of therapeutic strategies are generally based on gene mutations and cytogenetic abnormalities. Chem…
View article: Chemical Composition of Essential Oil from Citrus reticulata Blanco cv. Chachiensis (Chachi) and Its Anti-Mosquito Activity against Pyrethroid-Resistant Aedes albopictus
Chemical Composition of Essential Oil from Citrus reticulata Blanco cv. Chachiensis (Chachi) and Its Anti-Mosquito Activity against Pyrethroid-Resistant Aedes albopictus Open
The overuse of synthetic insecticides has led to various negative consequences, including insecticide resistance, environmental pollution, and harm to public health. This may be ameliorated by using insecticides derived from botanical sour…
View article: Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion
Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion Open
Purpose Despite chimeric antigen receptor (CAR) T-cell therapy has achieved great advances in recent year, approximately 50% of relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL) patients treated with CAR-T experience rela…
View article: “Cicada Out of the Shell” Deep Penetration and Blockage of the HSP90 Pathway by ROS‐Responsive Supramolecular Gels to Augment Trimodal Synergistic Therapy
“Cicada Out of the Shell” Deep Penetration and Blockage of the HSP90 Pathway by ROS‐Responsive Supramolecular Gels to Augment Trimodal Synergistic Therapy Open
Deep penetration and downregulation of heat shock protein (HSP) expression in multimodal synergistic therapy are promising approaches for curing cancer in clinical trials. However, free small‐molecule drugs and most drug vehicles have a lo…
View article: Network pharmacology-based investigation and experimental validation of the mechanism of Metformin in the treatment of acute myeloid leukemia
Network pharmacology-based investigation and experimental validation of the mechanism of Metformin in the treatment of acute myeloid leukemia Open
Metformin，a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leu…